| Biomarker ID | 878 |
| PMID | 22355332 |
| Year | 2012 |
| Biomarker | Elongation Factor 1A (EFA1) ; Zinc-alpha-2-glycoprotien ; Complement Compnent C6; Hemopexin ; Vitamin D-binding protien; cDNA FLJ53698; Histidine-rich glycoprotien; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; N-acetlymuramoyl-L-alanine amidase; Thyroxine-binding globulin |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated [Elongation Factor 1A (EFA1) (1.4 fold) ; Zinc-alpha-2-glycoprotien (1.3 fold) ; Complement Compnent C6 (1.2 fold); Hemopexin (1.2 fold); Vitamin D-binding protien (1.1 fold)];Downregulated [cDNA FLJ53698 (1.3 fold); Histidine-rich glycoprotien (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H1 (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H2 (1.4 fold); N-acetlymuramoyl-L-alanine amidase (1.4 fold); Thyroxine-binding globulin (1.5 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Progressing Vs Metastatic Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Samples were collected from 4 groups with 5 samples each:benign prostatic hyperplasia (BPH); ii) localised cancer with no evidence of progression, (non-progressing) (iii) localised cancer with evidence of biochemical progression, (progressin), and (iv) bone metastasis at presentation (metastatic). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p ≤0.01 |
| Method Used | 4-plex iTRAQ |
| Clinical | No |
| Remarks | represents biomarkers assessed individualy, + represents biomarkers assessed as a pair or panel |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | EEF1A1, AZGP1, C6, HPX, HRG, ITIH1, ITIH2, SERPINA7 |